Balanced Crystalloid Solutions for Acute Pancreatitis

• Status: Recruiting
• Trial end date: 2023-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients diagnosed with acute pancreatitis regardless of etiology, severity of disease, and prior attacks will be randomized in two groups. The intervention group will receive a balanced crystalloid (Plasmalyte) at a rate of 10 ml/kg during the first 60 min and then continued at 3 ml/kg/h for the next 72 hours. The control group will receive normal saline at the same rate.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital Rijeka
• Collaborator: University of Rijeka
• Treatments: Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• patients diagnosed with acute pancreatitis based on the revised Atlanta criteria who present to our hospital within 48 hours of symptoms onset, regardless of etiology, severity of disease, or prior episodes of acute pancreatitis

Exclusion Criteria:

• chronic pancreatitis

• liver cirrhosis (Child-Pugh B and C)

• chronic hearth failure (NYHA>II)

• acute coronary syndrome

• cardiovascular intervention within 60 days before randomization

• chronic obstructive pulmonary disease dependent of home oxygenator or acute exacerbation of chronic obstructive pulmonary disease

• chronic kidney disease (eGFR <30 ml/min/1.73 m2)

• concomitant biliary infection (cholecystitis, cholangitis)

• severe autoimmune disease

• chronic active infection (TBC, AIDS)

• metastatic malignant disease

• primary pancreatic neoplasm

• patients transferred from other hospitals

• pregnancy and ongoing breastfeeding

• not willing to participate